ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia - Episode 4

Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

, , , , ,

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

EP. 1: Current Front-Line Treatment Options for CLL in 2023
EP. 2: Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA
EP. 3: Strategies for Managing Treatment-Naïve CLL with High-Risk Features
Now Viewing
EP. 4: Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL
EP. 5: Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL
EP. 6: Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy
EP. 7: Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE
EP. 8: Expert Perspectives on Navigating Treatment Selection with BTKis in CLL
EP. 9: Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy
EP. 10: Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice
EP. 11: Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials
EP. 12: Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis
EP. 13: Expert Insights into Investigation Therapies for CLL
EP. 14: Future Perspectives on the Treatment Landscape for CLL